Cadonilimab Injection Application Scope

It is a recombinant humanized bispecific monoclonal antibody that simultaneously targets and blocks two immune checkpoint pathways: PD-1 (Programmed Cell Death Protein 1) and CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4).

Cadonilimab Injection Characteristics

Ingredients: Cadonilimab
Properties: Clear, colorless to light yellow liquid
Packaging Specification: 125 mg/10 mL/vial
Storage: Store refrigerated at 2–8°C (36–46°F). Keep in original carton to protect from light. Do not freeze
Expiry Date: 24 months from manufacturing date
Executive Standard: National Drug Standard
Approval Number: National Drug Approval Number S20220018
Date of Revision: 9.July.2025 (Please refer to the latest version of the package insert for the most current information)
Manufacturer: Zhongshan Kangfang Biopharmaceutical Co., Ltd

Guidelines for the Use of Cadonilimab Injection

Dosage and Administration:
- Recommended Dose:
  - For Cervical Cancer: The recommended dosage is 6 mg/kg body weight, administered via intravenous infusion every 2 weeks (Q2W) until disease progression or unacceptable toxicity occurs.
  - For Gastric or GEJ Adenocarcinoma: Please consult the latest official prescribing information for the specific recommended dosage regimen for this indication, as it may involve combination therapy.
- Administration: Administer as an intravenous infusion over approximately 60 minutes (±10 minutes). Do not administer as an intravenous push or bolus. Use a sterile, pyrogen-free, low-protein-binding in-line filter (pore size 0.22 or 0.2 μm) during infusion. Do not co-administer other drugs through the same infusion line.
- Missed Dose: If a dose is missed, administer it as soon as possible. Subsequently, adjust the dosing schedule to maintain the regular interval. Consult the treating physician for specific guidance.
Adverse Reactions:
- Common Adverse Reactions:
  - Fatigue: Reported in clinical trials
  - Rash: Skin reactions observed
  - Diarrhea: Gastrointestinal disturbances
  - Pruritus: Itching
- Serious Adverse Reactions:
  - Infusion-Related Reactions (IRRs): Symptoms include fever, chills, rash, and hypotension
  - Immune-Related Adverse Events (irAEs): Such as pneumonitis, hepatitis, colitis, and endocrinopathies
Contraindications:
- Hypersensitivity: Known allergy to cadonilimab or any component of the formulation
- Active Infections: Uncontrolled infections
- Autoimmune Disorders: Patients with active autoimmune diseases
Precautions:
- Monitoring: Regular monitoring for adverse reactions during treatment
- Pre-medication: Consideration for pre-medication to reduce the risk of infusion-related reactions
- Discontinuation: Discontinue if severe adverse reactions occur

Cadonilimab Injection Interactions

Concomitant Use: Use with other immunosuppressive agents may increase the risk of adverse reactions
Vaccinations: Avoid live vaccines during treatmen

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.